[Effect of olbetam on hyperlipidemia in NIDDM].
The effect of Olbetam on serum lipid and lipoproteins was studied in 30 diabetic patients with hyperlipidemia in four weeks trial. The dose of Olbetram was 500 mg/d. The results showed serum concentrations of TC, TG, and VLDL-C were decreased while HDL-C especially HDL2-C increased significantly after treatment. There were no significant changes in FBG, blood creatinine and urine acid. This result suggests Olbetam can improve dyslipidemia in NIDDM and was well tolerated by all patients.
Yu
Y
Y
Department of Endocrinology, First Affiliated Hospital.
Liang
J
J
Zhang
X
X
D000328:Adult; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000150:complications; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D015243:Cholesterol, VLDL; D000960:Hypolipidemic Agents; D011719:Pyrazines; D014280:Triglycerides; D002784:Cholesterol; C027696:acipimox